Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Zomedica Pharmaceuticals Corp. (ZOM)

0.347   -0.001 (-0.37%) 10-14 15:59
Open: 0 Pre. Close: 0.3483
High: 0 Low: 0
Volume: 0 Market Cap: 41M
Zomedica Pharmaceuticals Corp is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.38 - 0.382 0.382 - 0.384
Low: 0.345 - 0.348 0.348 - 0.35
Close: 0.346 - 0.35 0.35 - 0.353

Technical analysis

as of: 2019-10-14 4:49:49 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.47     One year: 0.54
Support: Support1: 0.31    Support2: 0.25
Resistance: Resistance1: 0.40    Resistance2: 0.46
Pivot: 0.34
Moving Average: MA(5): 0.34     MA(20): 0.36
MA(100): 0.30     MA(250): 0.71
MACD: MACD(12,26): -0.01     Signal(9):
Stochastic oscillator: %K(14,3): 34.86     %D(3): 29.95
RSI: RSI(14): 48.72
52-week: High: 1.85  Low: 0.20  Change(%): -79.8
Average Vol(K): 3-Month: 14106  10-Days: 9253

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
ZOM has closed below upper band by 46.7%. Bollinger Bands are 10.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2019-09-11
PCG Research Announces Publication of Report Covering Zomedica Pharmaceuticals Corp.
Developer of Diagnostic and Pharmaceutical Solutions for the Companion Animal Market with Commercialization Activities Approaching New York, New York--(Newsfile Corp. - September 11, 2019) - PCG Research, the equity research division of PCG Advisory, Inc., a leading investor relations and strategic advisory

2019-06-13
The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) EXACT Sciences Corporation (NASDAQ: EXAS ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 12) Acorda Therapeutics Inc (NASDAQ: ACOR ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Minerva Neurosciences Inc (NASDAQ: NERV ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) NextCure Inc (NASDAQ: NXTC ) Novavax, Inc. (NASDAQ: NVAX ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obseva SA (NASDAQ: OBSV ) RA Medical Systems Inc (NYSE: RMED ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sierra Oncology Inc (NASDAQ: SRRA ) Unum Therapeutics Inc (NASDAQ: UMRX ) Zomedica Pharmaceuticals Corp (NYSE: ZOM ) Stock In Focus Savara's Pulmonary Disease Drug Does Not Meet Primary Endpoint In Late-stage Study Savara Inc (NASDAQ: SVRA ) said a Phase 3 study dubbed IMPALA that evaluated its …

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE American
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty Generic
Shares Out. (M) 108.04
Shares Float (M) 53.23
% Held by Insiders 57.62
% Held by Institutions 3.47
Shares Short (K) 141
Shares Short P. Month (K)

Stock Financials

EPS -0.244
Book Value (p.s.) -0.040
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -191.4
Return on Equity (ttm) -393.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.223
Qtrly Earnings Growth
Operating Cash Flow (M) -17.72
Levered Free Cash Flow (M) -6.69

Stock Valuations

P/E -1.42
P/E Growth Ratio
P/BV -8.68
P/S
P/CF -2.12

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.